Literature DB >> 19098192

CT-guided radiofrequency ablation in the treatment of recurrent rectal cancer.

Giuseppe Belfiore1, Enrico Tedeschi, Francesco Michele Ronza, Maria Paola Belfiore, Ettore Borsi, Giovanni Pietro Ianniello, Antonio Rotondo.   

Abstract

OBJECTIVE: Locally recurrent rectal adenocarcinoma remains a therapeutic challenge that is unsatisfactorily managed by surgery and radiation therapy or chemotherapy. Palliative CT-guided radiofrequency ablation was used in 14 patients with recurrent rectal adenocarcinoma who had been previously treated with abdominoperineal resection and radiation therapy. Follow-up CT or MRI was performed at 3, 6, 12, and 24 months. Pain palliation was monitored by the brief pain inventory (BPI).
CONCLUSION: One month after radiofrequency ablation, 11 patients reported satisfactory BPI mean scores reduction compared to baseline (from 7.6 to 3.4 and from 5.1 to 1.6 for worst and average pain, respectively). In two unresponsive patients, retreatment was successfully performed at 3 months. After 24 months, worst and average pain scores further decreased (to 2.6 and 0.8, respectively) in 10 patients, who, at imaging, showed an ablation zone covering the entire original lesion in two patients and incomplete ablation in eight. In our experience, radiofrequency ablation is a safe and effective palliative treatment for patients with recurrent rectal adenocarcinoma.

Entities:  

Mesh:

Year:  2009        PMID: 19098192     DOI: 10.2214/AJR.07.2649

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  3 in total

1.  Clinical and instrumental assessment of herniated discs after nucleoplasty: a preliminary study.

Authors:  Alessandro Liguori; Federica Galli; Martina Gurgitano; Anna Borelli; Marco Pandolfi; Ferdinando Caranci; Alberto M Magenta Biasina; Giovanni G M Pompili; Claudia L Piccolo; Vittorio Miele; Carlo Masciocchi; Giampaolo Carrafiello
Journal:  Acta Biomed       Date:  2018-01-19

2.  CT-guided cryoablation for unresectable pelvic recurrent colorectal cancer: a retrospective study.

Authors:  Ying Wang; Xin-Hong He; Li-Chao Xu; Hao-Zhe Huang; Guo-Dong Li; Yao-Hui Wang; Wen-Tao Li; Guang-Zhi Wang
Journal:  Onco Targets Ther       Date:  2019-02-19       Impact factor: 4.147

Review 3.  Ablative therapies for colorectal polyps and malignancy.

Authors:  Jacqueline Oxenberg; Steven N Hochwald; Steven Nurkin
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.